EGFR inhibitor Tagrisso (osimertinib) has now become the first drug to show an improvement in overall survival (OS) in patients with early-stage, EGFR-mutated non-small cell lung cancer (NSCLC ...

SAVANNAH and ORCHARD Phase II trials show the addition of savolitinib or datopotamab deruxtecan-dlnk to TAGRISSO upon disease progression demonstrates strong clinical activity New study results ...

Results from multiple clinical trials showed that Tagrisso demonstrated survival benefits in ... safe and convenient treatment for patients with EGFR-mutated lung cancer across stages and lines of ...

which compared the combination of Rybrevant and Lazcluze against AstraZeneca’s AZN Tagrisso in first-line EGFR-mutated non-small cell lung cancer (“NSCLC”). Data from the study suggests that ...

It is estimated that 3,200 individuals will be diagnosed with lung cancer annually in Oklahoma. Early-stage detection significantly improves long-term survival rates compared to later-stage diagnoses.

As part of AstraZeneca’s ongoing commitment to treating patients as early as possible in lung cancer, Tagrisso is also being investigated in the early-stage adjuvant resectable setting in the ADAURA2 ...

LAURA Phase III trial of TAGRISSO in unresectable ... safe and convenient treatment for patients with EGFR-mutated lung cancer across stages and lines of treatment." Susan Galbraith, Executive ...

LAURA Phase III trial of TAGRISSO ... patient with lung cancer is to not only extend a patient's life but also maintain quality of life while on treatment. The continued overall survival trend seen ...